HLA-DR [TAL 1B5]

Product Description

HLA-DR (Human Leukocyte Antigen – DR isotype) is a major histocompatibility complex (MHC) class II antigen presentation molecule, critical for the activation of lymphocytes and the coordinating of adaptive immune responses. HLA DR antigen is required for tumor-associated antigen recognition by CD4+ T cells. It is normally expressed on antigen-presenting cells including monocytes, macrophages, dendritic cells and B cells, but expression can be induced on epithelial cells and tumor cells in response to inflammatory conditions.^15,16

Specifications

1. Kiernan JA. Histological and Histochemical Methods: Theory and Practice. New York: Pergamon Press 1981
2. Sheehan DC and Hrapchak BB. Theory and Practice of Histotechnology. St. Louis: C.V. Mosby Co. 1980
3. Clinical Laboratory Improvement Amendments of 1988: Final Rule, 57 FR 7163, February 28, 1992.
4. Shi S-R, Cote RJ, Taylor CR. J Histotechnol. 1999 Sep;22(3):177-92.
5. Taylor CR, et al. Biotech Histochem. 1996 Jan;71(5):263-70.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
7. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.
8. CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2) CLSI Wayne, PA USA (www.clsi.org). 2011
9. College of American Pathologists (CAP) Certification Program for Immunohistochemistry. Northfield IL. Http://www.cap.org (800) 323- 4040.
10. O’Leary TJ, Edmonds P, Floyd AD, Mesa-Tejada R, Robinowitz M, Takes PA, Taylor CR. Quality assurance for immunocytochemistry; Proposed guideline. MM4-P. National Committee for Clinical Laboratory Standards (NCCLS). Wayne, PA. 1997;1-46
11. Koretzik K, Lemain ET, Brandt I, and Moller P. Metachromasia of 3- amino-9-ethylcarbazole (AEC) and its prevention in Immunoperoxidase techniques. Histochemistry 1987; 86:471-478.
12. Nadji M, Morales AR. Immunoperoxidase, part I: the techniques and its pitfalls. Lab Med 1983; 14:767
13. Omata M, Liew CT, Ashcavai M, Peters RL. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen: a possible source of error in immunohistochemistry. AmJ Clin Path 1980; 73:626
14. Herman GE and Elfont EA. The taming of immunohistochemistry: the new era of quality control. Biotech & Histochem 1991; 66:194
15. Dunne MR, Phelan JJ, Michielsen AJ, et al. Characterising the prognostic potential of HLA-DR during colorectal cancer development. Cancer Immunol Immunother. 2020;69(8):1577-1588.
16. Matsushita K, Takenouchi T, Shimada H, et al. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferongamma in situ. Cancer Sci. 2006 Jan;97(1):57-63.

Ultraline antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Ventana Medical Systems, Inc or Roche. Biocare, Ventana and Roche are not affiliated, associated, or related in any way. Ventana®, BenchMark®, ultraView and OptiView are trademarks of Roche.

Q Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Leica Biosystems. Biocare and Leica Biosystems are not affiliated, associated, or related in any way. Leica, Leica Biosystems, BOND-MAX, and BOND-III are trademarks of Leica Biosystems.